Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study Our phase II trial randomly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback